This article was originally published by The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the...
Myeloma NZ
Newsletter: Spring 2020
Hello Everybody It is hard to believe that we are nearly two thirds through the year and what a year it has been. The COVID-19 pandemic has impacted...
Learning About Resources in Multiple Myeloma
This article was originally published by Cure Understanding Smoldering Multiple Myeloma Transcript: Kristie L. Kahl: Can you explain what...
Changing Patterns of Care in Multiple Myeloma
This article was originally published by AJMC Treatment Evolution in Multiple Myeloma Looking at the current state of multiple myeloma management,...
FDA Approves Daratumumab, Carfilzomib, Dexamethasone Triplet to Treat Multiple Myeloma
This article was originally published by Cancer Network The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib...
Berdeja Compares Later-Line Therapies in Multiple Myeloma
This article was originally published by Targeted Oncology As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, director of...
MRD, Biomarkers in Multiple Myeloma
This article was originally published by AJMC MRD Should Be More Widely Used in Clinical Care of MM, Report Argues Advances in scientists'...
Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma
This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer...
Exploring Challenges With CAR T Cells and NK Cells in Multiple Myeloma
This article was originally published by Targeted Oncology. C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at...
Upcoming patient seminar: Hamilton
Hamilton Myeloma Semimar, Saturday 5 September Come along to our Hamilton Myeloma Patient Seminar, hosted by MyelomaNew Zealand and Leukaemia &...
GSK nabs FDA approval for first-in-class multiple myeloma drug
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also...
Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma
For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In...